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Abstract
Long-term memory formation is known to be critically dependent upon de novo gene expression
in the brain. As a consequence, pharmacological enhancement of the transcriptional processes
mediating long-term memory formation provides a potential therapeutic strategy for cognitive
disorders involving aberrant neuroplasticity. Here we focus on the identification and
characterization of small molecule inhibitors of histone deacetylases (HDACs) as enhancers of
CREB (cAMP response element-binding protein)-regulated transcription and modulators of
chromatin-mediated neuroplasticity. Using a CREB reporter gene cell line, we screened a library
of small molecules structurally related to known HDAC inhibitors leading to the identification of a
probe we termed crebinostat that produced robust activation of CREB-mediated transcription.
Further characterization of crebinostat revealed its potent inhibition of the deacetylase activity of
recombinant class I HDACs 1, 2, 3, and class IIb HDAC6, with weaker inhibition of the class I
HDAC8 and no significant inhibition of the class IIa HDACs 4, 5, 7, and 9. In cultured mouse
primary neurons, crebinostat potently induced acetylation of both histone H3 and histone H4 as
well as enhanced the expression of the CREB target gene Egr1 (early growth response 1). Using a
hippocampus-dependent, contextual fear conditioning paradigm, mice systemically administered
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crebinostat for a ten day time period exhibited enhanced memory. To gain insight into the
molecular mechanisms of memory enhancement by HDAC inhibitors, whole genome
transcriptome profiling of cultured mouse primary neurons treated with crebinostat, combined
with bioinformatic analyses of CREB-target genes, was performed revealing a highly connected
protein-protein interaction network reflecting modules of genes important to synaptic structure and
plasticity. Consistent with these findings, crebinostat treatment increased the density of synapsin-1
punctae along dendrites in cultured neurons. Finally, crebinostat treatment of cultured mouse
primary neurons was found to upregulate Bdnf (brain-derived neurotrophic factor) and Grn
(granulin) and downregulate Mapt (tau) gene expression—genes implicated in aging-related
cognitive decline and cognitive disorders. Taken together, these results demonstrate that
crebinostat provides a novel probe to modulate chromatin-mediated neuroplasticity and further
suggests that pharmacological optimization of selective of HDAC inhibitors may provide an
effective therapeutic approach for human cognitive disorders.
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1.1 Introduction
Numerous studies have described a key role for the transcription factor CREB (cAMP
response element-binding protein) in neuroplasticity underlying learning and memory (Silva
et al., 1998; Benito & Barco, 2010; Sakamoto et al., 2011). Early work in Drosophila
melanogaster showed that CREB is required for olfactory memory (Yin et al., 1994).
Knockout of CREB in mice impairs fear conditioning memory (Bourtchouladze et al.,
1994). Finally, enhancement of hippocampal-dependent memory by histone deacetylase
(HDAC) inhibitors depends on CREB and its interaction with the coactivator CBP (CREB-
binding protein) (Vecsey et al., 2007). CBP has lysine acetyltransferase activity, and can
acetylate lysines in histone N-terminal tails. Pointing to the importance of these mechanisms
to human cognition, loss of function of CBP is known cause the human genetic disorder
Rubinstein-Taybi syndrome (Rubinstein & Taybi, 1963; Petrij et al., 1995), a congenital
neurodevelopmental disorder defined by characteristic postnatal growth deficiencies,
dysmorphology and intellectual disability. The identification of dysregulated histone
acetylation due to loss of CBP in Rubinstein-Taybi syndrome patients (Murata et al., 2001),
and in the corresponding mouse models (Alarcón et al., 2004; Korzus et al., 2004; Wood et
al., 2005), serves as one of the first examples of a now growing list of human diseases with
cognitive deficits that can be considered as ‘chromatinopathies’ due to causally involved
mutations in regulators of the structure or function of chromatin and gene expression
(reviewed in Levenson & Sweatt 2005; van Bokhoven 2011; Haggarty & Tsai 2011). In
addition to these primary chromatinopathies, it is also increasingly recognized that certain
neurodegenerative disorders with cognitive deficits, such as Alzheimer’s disease (Gräff et
al., 2012) and Huntington’s disease (Giralt et al., 2012), involve a significant component of
epigenetic dysregulation as a downstream consequence of disease pathophysiology. Taken
together, these findings point to CREB-mediated transcription as being of paramount
importance to the study of human cognitive disorders and efforts to develop novel cognitive
enhancers.
The CREB transcriptional pathway is activated by intracellular signaling triggered by
increases in intracellular cAMP concentration, or a variety of other signaling pathways
(Silva et al. 1998; Johannessen et al., 2004; Benito & Barco, 2010). Typically, the final
effector of these signaling pathways is a kinase that phosphorylates CREB at serine 133. The
coactivator histone acetyltransferase CBP is then recruited to phospho-(S133)-CREB, which
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is bound to cyclic-AMP response elements (CREs) in gene promoters. The complex of
CREB-CBP then interacts with the general transcriptional machinery to induce activation of
transcription of CREB target genes (Goldman et al., 1997). Termination of this
transcriptional pathway is mediated by phosphatases that dephosphorylate CREB (Mauna et
al., 2011). Finally, the pathway can also be downregulated by proteasome-mediated
degradation of CREB (Garat et al., 2006).
Inhibitors of HDACs regulate CREB-dependent transcription (e.g. Fass et al., 2003) and
enhance cognition (reviewed in Haggarty & Tsai, 2011). In the case of contextual fear
conditioning, enhancement of cognition by HDAC inhibitors is dependent on the
functioning of CREB (Vecsey et al., 2007). HDACs are a family of 18 isoforms that
catalyze the deacetylation of the ε-amino group of lysine side chains in histone N-terminal
tails, and also in numerous other intracellular proteins (Grozinger & Schreiber, 2002;
Choudhary et al., 2009). The catalytic mechanism of 11 of these HDACs is critically
dependent on a divalent zinc cation coordinated by conserved histidine and aspartate
residues within the catalytic site (Bressi et al., 2010). Zinc-dependent HDAC isoforms have
been categorized into classes based on structural analyses of the active sites and other
domains in these proteins and inhibitor sensitivity (Bradner et al., 2010): class I (HDACs 1,
2, 3, and 8); class IIa (HDACs 4, 5, 7, and 9); class IIb (HDACs 6 and 10); and class IV
(HDAC11).
The HDAC isoforms that regulate CREB-dependent transcription and cognition have not
been fully identified (reviewed in Fischer et al., 2010). HDACs could potentially regulate
CREB-dependent transcription via several mechanisms. First, HDACs could reverse CBP-
catalyzed histone acetylation events that mediate transcriptional activation (e.g Valor et al.,
2011). Indeed, an HDAC inhibitor failed to enhance cognition in mice with a focal depletion
of CBP in the hippocampus (Barrett et al., 2011). Second, HDACs could counteract CBP
and the related lysine acetyltransfrease p300 activation by auto-acetylation (Thompson et al.,
2004). Also, HDAC1- and HDAC8-protein phosphatase 1 complexes have been shown to
mediate CREB dephosphorylation (Canettieri et al., 2003; Gao et al., 2009). Further work
will be required to fully identify the HDAC isoforms that regulate CREB-dependent
transcription and cognition, and their mechanisms of action.
Here, we describe a chemical-genetic approach to identify novel HDAC inhibitors that
regulate CREB-dependent transcription, neuronal histone acetylation, and enhance learning
and memory in vivo.
2. Results
2.1 CREB reporter gene screen
To identify novel enhancers of CREB-dependent transcription, we used a PC12 cell line
stably transfected with a reporter gene driven by six tandem CREs (Figure 1A; Meinkoth et
al., 1990). CREB reporter gene induction by forskolin, an adenylate cyclase activator, is
triggered by an elevation of cAMP levels, which stimulates a well described pathway
involving protein kinase A (PKA)-mediated phosphorylation of CREB and recruitment of
CBP (Johannessen et al., 2004). Activation of this pathway is further enhanced by inhibition
of phosphodiesterase activity by rolipram (Xia et al., 2009). These facts underscore the
effectiveness of this reporter gene assay in identifying novel small molecules with memory
enhancing activity (Xia et al., 2009), such as rolipram (e.g. Hosseini-Sharifabad et al.,
2012).
Treatment with the forskolin (10 μM; 4 hours) produced ~4-fold induction of the CREB
reporter gene (Figure 1B). This inducible reporter gene signal was detectable when the cells
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were grown in 384-well microtitre plates in a format compatible with high-throughput
screening. Forskolin induction of this reporter gene is further enhanced by the HDAC
inhibitor trichostatin A (Fass et al., 2003; Figure 1B). We then used this assay to screen a
library of ~1,200 small molecules designed to inhibit HDACs (Tang et al., 2011; Figure 1C
and Supplementary Figure 1). These compounds contained one of three biasing elements—
metal chelating hydroxamic acid, which may bind to the zinc in the HDAC catalytic site;
ortho-hydroxy anilide; or carboxylic acid—that are present in known HDAC inhibitors. The
biasing elements were coupled to 4, 5, or 6 carbon linkers ending in a hydrazone moiety.
Reaction with aldehyde-containing “caps” resulted in a library of novel potential HDAC
inhibitors modeled after the classic “cap-linker-biasing element” structure of known HDAC
inhibitors (Figure 1C) (Grozinger & Schreiber, 2002; Cole, 2008; Tang et al., 2011).
The range of cellular activities of the compounds in the CREB reporter gene screen both in
the absence and presence of forskolin (4 hour treatments) are shown in Figure 1D. We found
compounds that activated the reporter gene in both conditions. Thus, we chose to focus on
compounds that enhanced reporter gene activation only in the presence of forskolin as a
means of selecting compounds that could target CREB-mediated transcription when CBP is
in an activated state due to PKA activation by cAMP. The structure of the most active
forskolin-dependent compound, which we termed “crebinostat”, is shown in Figure 1D.
To confirm that crebinostat was indeed an HDAC inhibitor, we resynthesized it and
confirmed its structure and purity (Supplementary Figures 1, 2), and then we tested its
ability to inhibit the enzymatic activity of a panel of recombinant HDACs 1-9. We used a
modified version of an in vitro assay with HDAC class-specific substrates (Bradner et al.,
2010) in which the HDACs deacetylate a tripeptide substrate derived from histone H4
acetylated lysine 12 (AcH4K12) residue, which is then cleaved by trypsin, releasing a
fluorophore (Fass et al., 2010). This substrate was chosen on the basis of its robust
deacetylation by class I HDACs, including HDAC2, as well as its relevance to cognition--
decreased acetylated histone H4 lysine 12 is found in the brain in mice showing ageing-
related cognitive decline (Guan et al., 2009; Peleg et al., 2010). Table 1 shows the IC50s for
inhibition of HDACs 1-9 by crebinostat, and for comparison, the related hydroxamic acid
SAHA (suberoylanilide hydroxamic acid). Crebinostat is approximately 10-fold more potent
than SAHA for inhibition of class I HDACs 1-3.
2.2 Regulation of neuronal histone acetylation by crebinostat
To test the cellular HDAC inhibitory activity of crebinostat, we measured its ability to
induce histone acetylation in mouse primary cultured forebrain neurons. We chose to focus
on AcH4K12 (the physiological correlate of our in vitro biochemical assay substrate), as
well as AcH3K9, because these acetylation states have been implicated in cognition
enhancement in normal and aged mice (Fischer et al., 2007; Guan et al., 2009; Peleg et al.,
2010). To quantify these acetylation marks, we developed a high throughput,
immunofluorescence-based assay using laser-scanning cytometry (Figure 2A;
Supplementary Figure 3). Treatment with crebinostat for 24 hr induced robust acetylation of
AcH4K12 and AcH3K9 in a dose dependent manner (Figure 2B). EC50 values were 0.29
μM and 1.9 μM (AcH4K12) and 0.18 μM and 1.0 μM (AcH3K9) for crebinostat and
SAHA, respectively. As predicted by its improved potency in the in vitro enzymatic assays,
crebinostat was ~6-fold more potent than SAHA at inducing histone acetylation in neurons.
To test for effects of crebinostat beyond these two particular acetylated residues on histone
H4 and histone H3, we also performed western blotting of chromatin isolated from
crebinostat-treated neurons with a general anti-acetylated lysine antibody (Figure 2C), which
revealed strong increases in acetylation of histone H3, histone H4 as well as histone H2A
and H2B, which are histone known to be hypo-acetylated upon loss of CBP in Rubinstein-
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Taybi syndrome patient lymphoblastoid cell lines (Lopez-Atalaya et al., 2012). Taken
together, these data indicate that crebinostat is a highly potent cell-active HDAC inhibitor
capable of altering histone acetylation states related to cognition enhancement in neurons.
2.3 Testing of crebinostat in contextual fear conditioning paradigm in mice
Our ultimate goal is to discover novel HDAC inhibitors that affect neuroplasticity not only
in vitro with cultured neurons but also in vivo to enhance learning and memory. In order to
first determine if crebinostat was brain penetrant upon systemic administration, a
pharmacokinetic profile was determined with a single IP dose (25 mg/kg) chosen to match
that used in the fear conditioning experiments. Crebinostat had a maximum concentration
(Cmax) in brain of 60 nM at 30 minutes post-injection, and a half-life (T1/2) of 0.72 hrs.
(Figure 3A; see Supplementary Figure 4 for more details). Given crebinostat’s enzymatic
activity IC50 values in the single digit nM range (Table 1), this level of brain exposure is
consistent with the concentrations needed to inhibit HDACs, particularly for HDAC1/2/3/6.
Furthermore, this exposure profile further defines the pharmacokinetic properties sufficient
for hydroxamate-based HDAC inhibitors to enhance memory—pulsatile, rather than
continuous, exposure, is sufficient.
Having determined that crebinostat was brain penetrant, we tested the effect of chronic (10
day) treatment with crebinostat (25 mg/kg), administered systemically via daily
intraperitoneal injections, on performance in a mouse contextual fear conditioning model
(Figure 3B). In this fear conditioning model, mice cease to locomote (“freeze”) in a context-
dependent manner once they have learned the association between the context and a
footshock given only in this context. Figure 3C shows that crebinostat produced robust
enhancement of context-dependent freezing behavior. Importantly, no significant differences
were detected between vehicle and crebinostat treated animal groups in exploratory activity
immediately prior to foot shock, indicating that chronic crebinostat treatment did not cause a
state-dependent effect that confounded the measurement of percent freezing post-shock
(Figure 3D). We also measured the effect of crebinostat injections on histone acetylation in
the hippocampus by giving one additional dose of crebinostat or vehicle 24 hours after the
fear conditioning test, and harvesting brains one hour after these injections. By western blot
analysis, we found that crebinostat induced a trend towards an increase in total hippocampal
acetylation of both H4K12 and H3K9, measured one hour after IP injection (Supplementary
Figure 5); however, this effect was ultimately not statistically significant. This lack of
correlation between changes in histone acetylation and the cognition enhancing effects of
crebinostat suggests that either the effects of crebinostat on the particular histone acetylation
marks we investigated are subtle, or transient in nature, or alternatively, that appropriate
pharmacodynamic markers for HDAC inhibitor-mediated cognition enhancement at various
time points and in different brain regions, still need to be discovered.
2.4 Regulation of Egr1 gene expression by crebinostat
In light of its robust cognition-enhancing effects, and with the desire of identifying other
pharmacodynamic markers of HDAC inhibitor-mediated cognitive enhancement, we next
sought to determine whether crebinostat would enhance the expression of CREB-target
genes thought to play a role in learning and memory. We chose to focus initially on Egr1, an
immediate early gene that is activated in the brain in animals undergoing memory training
tasks, and may be required for memory formation (Malkani et al., 2004). Furthermore, Egr1
was recently reported to be an HDAC2 target gene (Guan et al., 2009), as well as a member
of a gene set comprising a molecular signature for intellectual disability disorders
(Hashimoto et al., 2011). Egr1 is a CREB target gene, with two CREs in its proximal
promoter, along with binding elements for SRF/ELK and SP1 (Sakamoto et al., 1994; Tur et
al., 2010; see Figure 4A). Chromatin immunoprecipitation assays have shown that HDAC2
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also binds to the Egr1 promoter, and overexpression of HDAC2 suppresses neuronal Egr1
expression, making it a useful marker of chromatin-mediated neuroplasticity that may be
relevant to memory formation (Guan et al., 2009). Figure 4A shows that both crebinostat
and SAHA (24 hour treatments) induced Egr1-EGFP reporter gene activity in primary
cultured cortical neurons. Representative images of EGFP fluorescence from DMSO and
crebinostat-treated cultures are shown in Figure 4A. Crebinostat was again found to be more
potent than SAHA, consistent with its greater potency in inducing neuronal histone
acetylation. Finally, crebinostat also activated expression of endogenous Egr1 in primary
cultured neurons (Figure 4B). Taken together, these results demonstrate that crebinostat
treatment not only increases histone acetylation in neurons, but also leads to the regulation
of gene expression that is known to be involved in memory formation and other forms of
neuroplasticity.
One intriguing aspect of crebinostat regulation of Egr1 expression was that crebinostat
treatment alone induced Egr1 in mouse cortical neurons (Figure 4), whereas activation of the
CREB reporter gene in PC12 cells by crebinostat required the presence of forskolin (Figure
1). These data suggest that crebinostat regulation of CREB target genes can be dependent on
factors specific to individual cell types, gene promoters, and/or the concurrence of ongoing
signal transduction events in cells. To further explore the effects of crebinostat on gene
expression in cortical neurons in the context of neuronal stimulation, we treated cultures for
6 hours with the neuronal signaling inducers forskolin, KCl, or BDNF in the absence and
presence of crebinostat. We added crebinostat 18 hours prior to stimulation with the
signaling inducers, and maintained crebinostat in the cultures during the 6 hour stimulations.
Using a multiplexed, NanoString nCounter gene expression assay, which is based on direct
digital detection of mRNA molecules of interest, we measured the effects of these
treatments on the expression levels of 53 genes selected on the basis of previous
observations of their responsiveness to HDAC inhibitor treatments, or data suggesting them
as candidate genes involved in neuroplasticity induced by HDAC inhibition. For the vast
majority of the genes, crebinostat regulation was additive with signal inducer regulation
(Supplementary Table 5). However, Figure 4C shows one exception: crebinostat regulation
of Homer1 expression in cortical neurons was synergistic with BDNF stimulation. These
data, together with the Egr1 data (Figure 4B), underscore the notion that crebinostat
regulation of gene expression is dependent on gene promoter- and signaling context-specific
factors.
2.5 Analysis of the transcriptome of neurons treated with crebinostat
To further dissect the mechanism of cognition enhancement by crebinostat, and to identify
additional potential pharmacodynamic markers for HDAC inhibitor-mediated cognition
enhancement beyond those tested in our candidate gene approach described above, we
hypothesized that besides the CREB target gene Egr1, crebinostat would regulate the
expression of additional CREB target genes. To test this hypothesis, we generated whole
genome transcriptome profiles with Illumina bead arrays from samples of mouse primary
cultured neurons treated with crebinostat (1 μM) for 24 hrs. We analyzed triplicate samples
obtained in two replicate experiments involving DMSO and crebinostat treatment. After
normalizing the microarray data, the distributions of the data were remarkably consistent
across replicates and experiments. Upon applying a statistical significance threshold (p <
0.05), we found that crebinostat upregulated 624 genes and downregulated 706 genes by at
least 1.5 fold (Figure 5; Supplementary Figure 6; Supplementary Table 1).
To identify CREB target genes within the list of crebinostat regulated genes, we cross-
referenced published CREB ChIP-seq data sets (Kim et al., 2010; Martianov et al., 2010;
MacGillavry et al., 2011). We determined that 153 of the upregulated genes and 152 of the
downregulated genes are experimentally validated CREB target genes (Supplementary Table
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2). On the basis of their reported effects on cognition, synaptic function, or neuronal
development, a subset of the CREB target genes upregulated by crebinostat were selected
for further validation by RT-PCR (Table 2). Using independent neuronal cultures from those
used for the whole genome transcriptome analysis, crebinostat treatment was verified to
upregulate all of the genes in Table 2, with many showing greater fold-changes than
observed on the microarray format, likely due to signal compression inherent in microarray
data. These results provide strong validation of the original CREB reporter gene assay used
to identify crebinostat, and further underscore the importance of HDAC activity as a key
regulator of CREB-mediated transcription in cultured neurons.
To test the possibility that additional transcription factors were regulated by crebinostat, we
searched for enrichment for genes with promoters containing known binding sites for
specific transcription factors within the set of crebinostat regulated genes. To perform this
analysis, we used the gene set enrichment analysis tool (Subramanian et al., 2005) on the
Broad Institute’s MSigDB website (http://www.broadinstitute.org/gsea/msigdb/index.jsp).
This analysis revealed strong statistical enrichment for genes with promoters having binding
sites for several transcription factors, including SP1, MYC, and NFAT (Supplementary
Table 4). Further work will be required to fully analyze crebinostat regulation of
transcription mediated by these factors; however, for the remainder of the present study, we
focused on crebinostat regulation of CREB target genes.
2.6 Analysis of crebinostat responsive synaptic CREB target gene networks
We next examined the possibility that crebinostat regulation of CREB target gene
expression would modulate the activity of networks of proteins involved in synaptic
function in neurons. To perform this analysis, we cross-referenced published databases and
literature identifying synaptic proteins (Kennedy et al., 2005; Collins et al., 2006;
Pocklington et al., 2006; Waite & Eickholt, 2010; Bayes et al., 2011), and identified 38
synaptic CREB target genes regulated by crebinostat (10 upregulated and 28
downregulated). To visualize these networks, we input the lists of up- and down-regulated
synaptic CREB target genes, mapped to their human homologs, into the VisANT integrative
visual analysis tool for biological pathways and networks (www.visant.bu.edu) and queried
for protein-protein interactions between these and other proteins in the VisANT database.
The resulting networks, consisting of the up- or down-regulated synaptic CREB target gene
“nodes”, and protein-protein interactions illustrated as connecting lines (“edges”), are
illustrated in Figure 5 (C, D). The full set of interactions indicated in Figure 5 is contained in
Supplementary Table 3.
Several functional sub-networks (or “modules”) were evident within the crebinostat-
responsive CREB target gene synaptic interactome. First, amongst genes upregulated by
crebinostat (Fig. 5A), one module consisted of five components of the protein translational
machinery. One protein in particular, Eef2, has been reported to respond to synaptic activity
by mediating local dendritic synthesis of BDNF (Verpelli et al., 2010). Mice with deficient
activity of the kinase that phosphorylates and activates Eef2 (Eef2k) show impaired
associative learning (Gildish et al., 2012). In addition, crebinostat upregulation of CTNNA1
(α-catenin) is expected to impact a module, including CTNNB1 (β-catenin) that plays an
important role in synaptic plasticity (Magushak & Ressler, 2012). A module of 13 proteins
regulating neurite outgrowth or the cytoskeleton was apparent within the set of synaptic
CREB target genes downregulated by crebinostat (Fig. 5B). Three of these downregulated
proteins (DPYSL4, DPYSL5, and OMG) are known to negatively regulate neurite
outgrowth (Kottis et al., 2002; Aylsworth et al, 2009; Brot et al., 2010). In addition, one
downregulated protein (CTNND2) was reported to be a negative regulator of β-catenin
signaling (Bareiss et al., 2010). Lastly, two of the downregulated proteins (CDK5R1 and
MAPT) are dysregulated under pathological conditions of neurodegeneration (Iqbal et al.,
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2010; Su & Tsai, 2011). These computational analyses suggest that HDAC inhibitors such
as crebinostat can enhance memory by regulating modules of genes that function together to
coordinate key changes in synaptic physiology.
2.7 Characterization of the effect of crebinostat on synapse formation
The observation that several of the CREB target genes upregulated by crebinostat promote
synapse formation, organization, and stability led us to hypothesize that crebinostat would
regulate some aspect of synapse morphology in our primary mouse forebrain cultures. To
test this hypothesis, we used immunofluoresence staining to detect synapsin I punctae along
dendrites identified as Map2-positive. While our previous experiments investigating
crebinostat’s effect on histone acetylation were performed in primary neuronal cultures
grown in 96-well plates, these synaptic morphology experiments were performed on cultures
grown on glass coverslips, featuring a lower density of neurons to allow more precise
determination of neuronal process morphology using higher resolution imaging. Figure 6
shows that, in these cultures, crebinostat treatment (1 μM) for 24 hrs produced a robust
increase in histone acetylation, as we observed in our 96-well plate cultures. This treatment
with crebinostat produced no detectable toxicity (Supplementary Figure 7). Although the
effect of crebinostat on histone acetylation was apparent and statistically significant when
mean nuclear intensity was quantified (Figure 6I); this effect was even larger when imaged
nuclei were parsed into signal intensity bins, and the data were analyzed to determine the
percentage of nuclei crossing a “high” signal intensity threshold (Figure 6J).
In addition to its effect on neuronal histone acetylation, crebinostat produced a visually
apparent increase in the number of synapsin I punctae along Map2-positive dendrites
(Figure 6C versus 6D; Figure 7A). To quantify crebinostat’s effects on dendritic synapsin I
punctae, we analyzed images using ImageJ image processing and analysis software. First,
we determined that crebinostat did not alter total dendrite length per image (Figure 7C),
indicating that crebinostat did not produce a gross change in neuronal morphology. Second,
we found that crebinostat did not alter synapsin I punctae size or staining intensity of those
punctae that could be measured (Figure 7D, E). Thus, there was no difference in the
detectability of synapsin I punctae staining signals between control and crebinostat-treated
cultures. Finally, we found that crebinostat treatment produced a nearly 2-fold increase in
dendritic synapsin I punctae density (Figure 7B). We propose that crebinostat may increase
synaptic density by upregulating the expression of genes involved in synaptic formation or
maintenance, which we speculate may be involved in its enhancement of memory formation.
The effect of crebinostat on synaptic density seen here is consistent with evidence for a key
role of HDAC2 in regulating synaptic density in vivo (Guan et al., 2009).
2.8 Regulation of genes implicated in human cognitive disorders by crebinostat
Given the ability of crebinostat to regulate chromatin-mediated neuroplasticity at the level of
CREB target genes involved in synaptic structure and plasticity along with its ability to
enhance memory in mice raises the question of whether crebinostat could reverse molecular
pathology underlying human diseases of cognition. Frontotemporal dementia is a hereditable
form of dementia, primarily involving behavioral and language deficits that can be caused
by haploinsufficiency at the Grn gene (granulin) locus (Gass et al., 2006). A recent report
indicated that the HDAC inhibitor, SAHA, can upregulate the expression of Grn (granulin)
in cell lines (Cenik et al., 2011). Indeed, here we extend these results by demonstrating that
crebinostat can also upregulate Grn mRNA expression in mouse forebrain primary neuronal
cultures (Figure 8A). Mutations in the Mapt gene encoding the microtubule-associated
protein tau can also cause FTD (Lee at al., 2001). These gain-of-function mutations lead to
pathological aggregation of tau in neurons. We found that crebinostat downregulated Mapt
mRNA expression in primary cultured neurons (Figure 8B). A reduction in the expression of
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aggregating forms of tau might help reverse cognitive deficits (Sydow et al., 2011). In
addition, overexpression of the heat shock protein HSP70 can induce clearance of
neurotoxic amyloid-β peptide in a mouse model of Alzheimer’s disease (Hoshino et al.,
2011). Indeed, crebinostat also upregulated Hspa1b (Hsp70) mRNA expression in primary
cultured neurons (Figure 8C). Lastly, crebinostat also upregulated Bdnf mRNA expression
(Figure 8D). In support of the potential therapeutic relevance of these findings, several lines
of evidence suggest that elevating the level of BDNF in the brain might enhance
neuroplasticity and produce therapeutic benefit in disorders of cognition (Nagahara &
Tuszynski, 2011). BDNF has also been implicated recently as a key factor in the
consolidation of fear memory and in reversing ageing-related cognitive decline (Lubin et al.,
2008; Zeng et al., 2011). Taken together, these data demonstrate the ability of crebinostat to
regulate the expression of key genes involved in neuroplasticity.
3. Discussion
Recent molecular, cellular, and behavioral studies indicate that pharmacological inhibition
of HDACs can ameliorate cognitive deficits produced by ageing or neurodegeneration
(Guan et al., 2009; Peleg et al., 2010; Fischer et al., 2010; Gräff et al., 2012). Harnessing the
therapeutic potential of HDAC inhibitors linked to cognitive enhancement requires
knowledge of the specific HDAC family member(s) involved, and the downstream
transcriptional pathways regulated by these HDACs that may be involved in memory. With
the long-term goal of determining if these HDAC-regulated pathways can be targeted for
therapeutic benefit in the context of disorders of cognition, we have sought to identify
improved small-molecule probes of HDACs relevant to neuroplasticity. Figure 9 shows
potential mechanisms by which one such probe molecule, crebinostat, could have these
effects by enhancing CREB-dependent transcription (see Introduction and Results for
details).
Crebinostat was selected from amongst a library of over 1,200 small molecules designed to
target the HDAC family (Tang et al., 2011) on the basis of its strong activity in the primary
CREB reporter gene assay. Consistent with its strong cellular activity, crebinostant was
found to potently inhibit the class I HDACs 1, 2, 3, and class IIb HDAC6, and to a lesser
extent the class I HDAC8 (Table 1), suggesting that one or more of these isoforms repress
CREB-dependent transcription. Indeed, HDAC1 has been reported to promote CREB
dephosphorylation through the recruitment of PP1 (Canettieri et al., 2003). In addition,
HDAC2 has recently been demonstrated to repress transcription of the CREB target genes
Egr1 and cFos in the brain (Guan et al., 2009). Finally, epistasis experiments in C. elegans
indicate that HDAC3 can oppose CREB-mediated neuroprotection (Bates et al., 2006).
While our data with crebinostat do not support a role for class IIa HDACs, it has been
reported that HDAC4 can repress CREB-dependent transcription (Bolger & Yao, 2005).
Moreover, we were not able to study the effects of crebinostat on the enzymatic activity of
HDACs 10 and 11 in vitro due to current limitations in our ability to develop robust
biochemical assays for these isoforms, and thus the role of these two HDACs is uncertain.
Further work will be required to fully elucidate which HDAC isoforms repress CREB-
dependent transcription, and whether different isoforms play distinct roles in a cell-type
specific or signaling-dependent manner. It will also be important to determine whether class
I HDAC isoform-selective inhibitors can enhance CREB-dependent transcription and
cognition.
Our results demonstrating that crebinostat treatment increases the number of synapsin I
positive punctae, reflective of the assembly and clustering of pre-synaptic vesicles along
Map2 staining dendrites, are consistent with those described by our group recently for a
structurally related HDAC inhibitor, synapsinostat, which we showed could enhance
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synaptogenesis in a microfluidics-based co-culture assay (Shi et al., 2012). However, data
reported here indicate that crebinostat is capable of either enhancing the formation of
synapses, or preventing their loss, or both, and both the pre-synaptic and post-synaptic
contributions to this process occur in primary cultured mouse neurons tested here, in
contrast to the artificial conditions of the co-culture assay.
Our transcript profiles generated from primary mouse neurons treated with crebinostat
allowed genome-wide assessment of the effects of a memory enhancing probe on the
regulation of gene expression. As anticipated from early studies on the effects of HDAC
inhibitors on CREB-mediated transcription (Fass et al., 2003), as well as systematic studies
of neural-activity dependent changes in gene expression (Benito et al., 2011), we observed
both upregulation and downregulation of gene expression. The analyses performed here,
particularly the intersection with global datasets of promoter occupancy by CREB through
chromatin immunoprecipitation experiments, and synaptome constituent identification
proteomic studies, represent one of the first efforts to generate a complete picture of the
synaptic regulatory protein interaction network modulated by activation of CREB target
genes by an HDAC inhibitor that is known to enhance cognition in mice. We found that
crebinostat upregulated the expression of several experimentally validated CREB target
genes (Table 2) that have been reported to play a role in cognition, synaptic function, or
neuronal development. For example, one of the networks of genes regulated in our
expression profiling in response to crebinostat was that of the Ras GTPase pathway.
Dysregulation of Ras-MAPK signaling has been implicated in multiple human genetic
disorders that include cognitive deficits, including neurofibromatosis, Noonan syndrome,
Costello syndrome, LEOPARD syndrome, CFC syndrome, and Legius syndrome (reviewed
in van Bokhoven, 2011). Thus, beyond Rubinstein-Taybi syndrome, these findings point to a
potential broader application of HDAC inhibitors in treating intellectual disabilities,
although the specific consequence of each disease causing mutation on downstream
signaling and how these altered neuronal cell states respond to HDAC inhibitor treatment
will need to be carefully investigated.
It is possible that there are additional CREB target genes in our list of transcripts
upregulated by crebinostat (Supplementary Table 1)—these genes might be identified in
future CREB ChIP-seq studies performed on brain tissue. It will be important to identify the
full set of CREB target genes that are regulated in the brain by crebinostat, and to determine
which of these contribute to the cellular events that mediate its effect on synapse density and
enhancement of memory. It will also be important to fully understand how the proteins
encoded by these CREB target genes interact to form networks that modulate synaptic
physiology in the brain (Figure 7). A full understanding of these networks will allow us to
identify critical modules that drive and control network activity—these modules may be
ideal targets for effective therapeutic intervention in disorders of cognition and altered
neuroplasticity.
While not addressed here, it will be important to consider the regulation of acetylation of
non-histone substrates as part of gaining a comprehensive understanding of the role of
HDACs in mediating cognition and neuroplasticity. For example, Yeh et al. (2004)
implicated acetylation of the transcription factor NF-kappaB in memory formation, although
the precise HDACs involved in mediating this effect and its relevance to different types of
memory and forms of neuroplasticity remain unclear. More recently, quantitative proteomics
studies performed in non-neuronal cell lines have identified a total of 1,750 acetylated
proteins and 3,600 individual lysine acetylation sites in these proteins (Choudhary et al.,
2009), many of which were sensitive to HDAC inhibitors such as SAHA. Taken together,
these findings point to the need in the future better understand the possible contribution of
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non-histone substrates to the short-term and long lasting effects of HDAC inhibitors such as
crebinostat on neuroplasticity. Indeed, such studies are ongoing in our lab.
While there are attractive features of crebinostat as a probe of chromatin-mediated
neuroplasticity and memory, there are limitations to the in vivo pharmacological properties
of crebinostat as revealed by the analysis of the brain-to-plasma Cmax ratio of 0.02, exposure
(AUClast) ratio of 0.02, and T1/2 in brain of ~43 min following IP administration of
crebinostat (Supplementary Figure 4). Now that these limitations are known, future
optimization of the pharmacological properties of this series of memory enhancers will aim
to increase overall brain exposure and the brain:plasma ratio. While ultimately the optimal
exposure profile for HDAC inhibitors for memory enhancement remains to be rigorously
determined, and may vary for different behavioral paradigms, we speculate that the pulsatile
nature of crebinostat exposure in the brain may be advantageous for the following reasons:
1) a pulsatile type of exposure may mimic aspects of salient cognitive experiences that occur
in short duration yet induce long-lasting memories; 2) pulsatile exposure has been reported
to be optimal in inducing neuroprotection (Langley et al., 2008); and 3) pulsatile exposure
may minimize undesired effects of long-term HDAC inhibition. An interesting challenge for
future studies will be to understand and delineate, amongst different classes of HDAC
inhibitors, with different binding kinetics and residence times on different HDAC targets,
which parameters determine the optimal pharmacokinetic profiles for HDAC inhibition
leading to memory enhancement and other behavioral effects.
4. Conclusions
In summary, a critical step in the probe development efforts summarized here that lead to
the identification of the novel memory enhancer crebinostat was to demonstrate efficacy in
neuronal cell-based assays that read out 1) HDAC-regulated acetylation; and 2)
transcriptional processes that can be related to mechanisms implicated in learning and
memory. In particular, acetylation of histone H4 lysine 12 (AcH4K12), CREB-dependent
transcription, and Egr1 expression all have been linked with synaptic plasticity and memory
(Benito & Barco, 2010; Sakamoto et al., 2011; Malkani et al., 2004; Guan et al., 2009; Peleg
et al., 2010; Fischer et al., 2010). With our ability to perform these assays in miniaturized
forebrain and cortical primary neuronal cultures in 96-well plates, in combination with the
use of in vitro enzymatic assays to assess potency toward recombinant HDACs that have
been validated with other known memory enhancers targeting HDACs (Fass et al., 2010),
we are now poised to screen new libraries of small molecules to identify novel HDAC
inhibitors that enhance learning and memory. We expect that our future screening efforts
will identify novel compounds with diverse patterns of HDAC isoform selectivity, potency,
and structural properties that can be optimized further for in vivo use. A recent example of
our efforts in this direction has been the identification of a novel class of macrocyclic
HDAC inhibitors, from a screen of a stereochemically and skeletally diverse library of small
molecules (Marcaurelle et al., 2010), that display complex mixed competitive/non-
competitive enzyme inhibition kinetics, and that were capable of increasing AcH4K12 levels
in our primary mouse neuronal culture. It is anticipated that the systematic testing of such
small-molecule probes in our platform of cellular assays and in vitro enzymatic assays will
lead to the discovery of a novel class of CREB-enhancing HDAC inhibitors, as well as small
molecules targeting other epigenetic mechanisms, that will potentially be useful as
therapeutics for neurodegenerative and neuropsychiatric diseases that involve dysregulated
chromatin-mediated neuroplasticity.
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Materials and Methods
CREB reporter gene assay
PC12 cells with a stably incorporated 6X-CRE-β-galactosidase CREB reporter gene
(Meinkoth et al., 1990) were seeded into poly-D-lysine coated 384-well plates at a density of
25,000 cells per well. The following day, cells were treated with HDAC inhibitors (20 μM)
in the absence or presence of forskolin (10 μM) for 4 hours. Cells were then processed for a
β-galactosidase assay (Applied Biosystems Galacto-Star) according to the manufacturer’s
instructions, and luminescence was read on an Envision plate reader (Perkin-Elmer).
In Vitro HDAC enzymatic assays
Assays were run in 384-well plates with recombinant HDACs 1-9 (BPS Bioscience) under
conditions appropriate for Michaelis-Menten kinetic analysis with the use of acetylated
tripeptide substrates at Km that are amide-coupled to 7-amino-4-methylcoumarin that can
detect either class I/IIb (substrate MAZ1600) or class IIa/HDAC8 (substrate MAZ1675)
HDAC activity exactly as described in Fass et al., 2010.
Neuronal histone acetylation assays
Mouse primary neuronal cultures were generated in factory precoated poly-D-lysine black/
clear bottom 96-well plates (BD Biosciences #BD356692) treated overnight with 75 l/well
of laminin [0.05 mg/ml] (Sigma #L2020) in PBS buffer. E17 embryonic mouse forebrain
was dissociated into a single cell suspension by gentle trituration following trypsin/DNAse
digestion (trypsin: Cellgro #25-052-Cl; DNAse: Sigma #D4527). Cells were plated at a
density of 12,500 cells per well in 100 l of Neurobasal medium (Gibco #21103-049)
containing 2% B27 (Gibco #17504-044), 1% Penicillin/Streptomycin/Glutamine (Cellgro
#30-009-CI) and cultured at 37°C with 5% CO2. After 13 days, cultures were treated with
HDAC inhibitors by pin transfer of compound (185 nl per well) using a CyBi-Well vario
pinning robot (CyBio Corp., Germany) and subsequently incubated for 24 hrs at 37°C with
5% CO2. Cells were then fixed with 4% formaldehyde for 10 min. Following two washes
with phosphate-buffered saline, cells were permeabilized and blocked with blocking buffer
composed of 0.1% Triton X-100, 2% BSA in PBS. For immunofluorescence imaging of
histone modifications, cells were stained with anti-acetyl-H3K9 (Millipore, cat# 07-352) or
anti-Ac-H4K12 (Millipore, catalog #04-119) antibodies, and Alexa488-conjugated
secondary antibody (Molecular Probes). Cellular nuclei were identified by staining with
Hoechst 33342 (Invitrogen, H3570). Cell nuclei and histone acetylation signal intensity were
detected and measured using a laser-scanning microcytometer (Acumen eX3, TTP Laptech).
Acumen Explorer software was used to identify a threshold of histone acetylation signal
intensity such that, in the absence of HDAC inhibitor, >99.5 % of cells had intensity levels
below the threshold. In the presence of HDAC inhibitors, cells with histone acetylation
signal intensities above the threshold were scored as “bright green nuclei”. The percentage
of nuclei scoring as bright green was quantified for each HDAC inhibitor. This percentage
was then normalized to DMSO controls.
Western blotting of neuronal histone acetylation
Protein lysates were collected from mouse forebrain primary cultures grown in vitro for 13
days (DIV13) on poly-D-lysine/laminin-coated 6-well plates (2 million cells/well) and
treated with DMSO or crebinostat (1 μM) for an additional 24 hours. Western blotting was
performed using standard conditions and immunoblotting with a general anti-acetylated
lysine antibody (Cell Signaling Technology, catalog #9814). Histone H2A, H2B, H3, and
H4 bands were identified by molecular weight and comparison to staining patterns of
antibodies for the individual histones.
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Egr1 reporter gene assay
Assays were conducted on mouse cortex primary neuronal cultures from transgenic animals
expressing an Egr1-EGFP reporter gene exactly as described in Guan et al., 2009.
NanoString nCounter gene expression assay
Mouse forebrain primary cultures, grown in poly-lysine- and laminin-coated 6-well plates,
were treated for 24 hours with DMSO or crebinostat (1 μM) starting on DIV13. During the
last 6 hours of this treatment, neuronal stimuli (or vehicle) were added at the following
concentrations: forskolin (50 μM); KCl (55 mM); or BDNF (20 ng/ml). RNA was isolated
with the RNeasy kit (Qiagen) according to the manufacturer’s instructions. Triplicate
samples were collected and analyzed using Nanostring nCounter Analysis System according
to the manufacturer’s instructions (http://www.nanostring.com/products/
gene_expression.php). A custom CodeSet was designed to probe for 53 genes listed in
Supplementary Table 5. See Supplementary Table 6 for this list of probes, as well as
negative and positive control probes, contained in the CodeSet. Raw data were background
subtracted using negative control probes, and then normalized to the average signal from the
positive control probes.
Transcriptome profiling
Mouse forebrain primary cultures, grown in poly-lysine- and laminin-coated 6-well plates,
were treated for 24 hours with DMSO or crebinostat (1 μM) starting on DIV13. RNA was
isolated with the RNeasy kit (Qiagen) according to the manufacturer’s instructions. cDNA
was synthesized using ArrayScript (Ambion). Triplicate samples from two independent
cultures (total n=6) were collected and analyzed using Illumina mouse whole-genome-6
microarrays. Total RNA from the samples was normalized to 20 ng/μl, and the Illumina
TotalPrep-96 RNA Amplification Kit (Applied Biosystems, PN #4393543) protocol was
used for amplification in a semi automated process. The total RNA underwent reverse
transcription to synthesize first-strand cDNA. This cDNA was then converted into a double-
stranded DNA template for transcription. In vitro transcription synthesized aRNA and
incorporated a biotin-conjugated nucleotide. The aRNA was then purified to remove
unincorporated NTPs, salts, enzymes, and inorganic phosphate. Labeled cRNA was
normalized to 150 ng/μl and hybridized to Illumina’s MouseWG-6 v2.0 Expression
BeadChip. The labeled RNA strand was hybridized to the bead on the BeadChip containing
the complementary gene-specific sequence. After a 16 hr hybridization, the beadchips were
washed and stained using a Cy3 streptavidin conjugate. Illumina’s BeadArray Reader was
used to measure the fluorescence intensity at each addressed bead location. Raw data were
annotated with Genome Studio (Illumina), and then quantile normalized and baseline
transformed to the median of the DMSO control samples using GeneSpring software
(Agilent). Probes failing to score as “present” in 100% of samples from at least one
treatment condition (DMSO or crebinostat) were removed. A statistical threshold (p < 0.05,
paired t-test with Benjamini-Hochberg multiple comparisons correction) and a fold change
criterion (1.5) were then applied to generate lists of genes up- and down-regulated by
crebinostat. All raw data will be deposited at NIH Gene Expression Omnibus (GEO)
Database.
Protein-protein interaction network analysis
Mouse genes scoring in the Illumina microarray data as upregulated by crebinostat were
cross-referenced to published lists of CREB target genes identified in ChIP-seq experiments
(Kim et al., 2010; Martianov et al., 2010; MacGillavry et al., 2011). Synaptic CREB target
genes were identified by cross-referencing published databases and literature identifying
synaptic proteins (Kennedy et al., 2005; Collins et al., 2006; Pocklington et al., 2006; Waite
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& Eickholt, 2010; Bayes et al., 2011). Gene symbols for all crebinostat-regulated synaptic
CREB target genes were converted to human orthologs and loaded as nodes into the
VisANT (http://visant.bu.edu/). Searches conducted with nodes consisting of the crebinostat
up- and down-regulated synaptic CREB target genes produced the protein-interaction
networks shown in Figure 5 C and D, respectively.
Quantitative RT-PCR assays of gene expression
Primary culture treatments, RNA isolation, and cDNA synthesis were performed as
described for the Illumina microarray experiments. mRNA levels for crebinostat-regulated
genes were measured by quantitative real-time PCR using TaqMan probe sets (Applied
Biosystems) and normalized to levels of Gapdh mRNA.
High resolution neuronal histone acetylation and synapsin I punctae imaging
Mouse primary forebrain cultures were grown on glass coverslips coated with poly-lysine
and laminin. Cultures were treated with DMSO or crebinostat (1 μM) for 24 hrs and then
processed for immunofluorescence staining according to standard methods (4%
formaldehyde fixation, 1 hour at 25°C), followed by staining with AcH4K12, Map2, and
synapsin I antibodies (Millipore, catalog number 04-119; EnCor Biotechnology, catalog
number CPCA-MAP2; Synaptic Systems, catalog number 106001) and standard
fluorophore-coupled secondary antibodies. Fluorescent images were acquired on a Zeiss
Axio Observer.Z1 microscope with a 63X objective. To quantify AcH4K12 fluorescence,
signal intensity of 10-25 nuclei was measured from duplicate crebinostat or DMSO
treatments in three independent cultures. To quantify synapsin I punctae, z-stacks (step size
0.5 m) were acquired from 15 sites on coverslips from three independent cultures, treated
with DMSO or crebinostat, using a Leica confocal microscope with a 40X objective. Z-
stacks were exported to ImageJ (http://rsbweb.nih.gov/ij/) and collapsed into single images
for further processing. After applying thresholds delimiting specific signals (held constant
over all images), Map2 staining was skeletonized, and total dendrite length was quantified as
the total length of the skeletonized image. Next, Map2 staining was dilated to create a
dendrite mask. Total size and intensity of synapsin I puntae staining contained within the
dendrite mask were measured. The density of synapsin I punctae was determined as the ratio
of number of synapsin I punctae over total dendrite length.
Animals
All mice used in this study for behavior were male C57BL/6J mice (9-10 weeks old)
obtained from the Jackson Laboratory (Bar Harbor, ME). Mice were housed under 12:12
light/dark cycles, with food and water available ad libidum. Transgenic Tg(Egr1-
EGFP)GO90Gsat mice containing the Egr1-EGFP bacterial artificial chromosome (BAC)
reporter gene (BX1225) were obtained originally on an FVB/NTac background from the
Jackson Laboratory (Bar Harbor, ME) and maintained through backcrossing to C57BL/6J
mice. Positive mice were detected through EGFP fluorescence. Embryos of heterozygous
mice were used for generating cortical neuron cultures. All procedures were performed in
accordance with the Committee for Animal Care of the Division of Comparative Medicine
at the Massachusetts Institute of Technology and with the National Institutes of Health
(NIH) Guide for the Care and Use of Laboratory Animals: Eighth Edition. Pregnant female
C57BL6/J mice used for generating embryonic cultures of neurons for histone acetlyation
and gene expression analysis were obtained from the Jackson Laboratory (Bar Harbor, ME).
Mice were housed under 12:12 light/dark cycles, with food and water available ad libidum.
All procedures were performed in accordance with the Massachusetts General Hospital
Subcommittee on Research Animal Care and with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals: Eighth Edition. All possible efforts were
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made to minimize animal suffering, to reduce the number of animals used, and to utilize
alternatives to in vivo techniques.
Compound administration
Crebinostat was administered in a vehicle consisting of 5% DMSO, 30% Cremophor, and
65% saline via daily intraperitoneal injections (25 mg/kg) for 10 days alternating daily
between left and right sides of the abdomen prior to behavioral testing with an additional
dose 1 hr after training on day 11.
Measurement of crebinostat concentration in the brain and plasma
A total 27 C57BL/6 mice were weighed before dose administration. Mice were dosed
intraperitoneally with a solution formulation of crebinostat at 25 mg/kg dose. Blood samples
(approximately 60 L) and tissues (brain) were collected from a set of three mice at pre
determined time points (pre-dose, 0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 hr). Immediately after
collection of blood, brain tissues were collected from a set of three mice at the same time
point. Plasma was harvested by centrifugation of blood and stored below −70°C prior to
analysis. Brain samples were homogenized using ice-cold phosphate buffer saline (pH 7.4)
and homogenates were stored below −70°C prior to analysis. Total homogenate volume was
three times the tissue weight. Crebinostat was detected in plasma and brain homogenates by
LC-MS/MS. The plasma and brain concentration-time data for crebinostat were used for the
pharmacokinetic analysis. Brain concentrations were converted to ng/g from ng/mL
considering total homogenate volume and brain weight where the density of brain was
considered as 1, which is equivalent to plasma density. Pharmacokinetic analysis was
performed using NCA module of WinNonlin Enterprise Version 5.2.
Behavioral procedures for contextual fear conditioning and open field locomotion
For contextual fear conditioning training, mice were placed in a TSE Multi-conditioning
System training chamber (the context) for a period of 3 minutes followed by two foot shocks
(2 seconds; 0.8 mA constant current) applied 30 seconds apart. After the last shock, the mice
remained in the chamber for an additional 15 seconds before being returned to their home
cage. The memory test was performed 24 h later by re-exposing the mice to the conditioning
context for 3 minutes. Freezing, defined as the lack of movement (except for respiration)
with an associated crouching posture, was recorded every 10s by a trained observer for 3
minutes (a total of 18 sampling intervals). Freezing was expressed as a percentage of the
number of positive freezing observations divided by the total number of sampling intervals
(18). Open field locomotion was the amount of horizontal movement (distance traveled in
cm) in the training chamber recorded during the first three minutes of the contextual fear-
conditioning training procedure, prior to shock administration, using the TSE Fear
Conditioning software package.
Chemical synthesis of novel HDAC inhibitors
A library of compounds was made following a published procedure using hydrazone
coupling chemistry (Vegas et al., 2007; Patel et al., 2009; Tang et al., 2011). HDAC
inhibitor biasing elements coupled to 4, 5 or 6 carbon linkers ending in a hydrazone bond
were reacted with aldehyde-containing caps (see scheme in Figure 1C). QC of the
synthesized compounds was performed on a Waters 2545 HPLC equipped with a 2998 diode
array detector, a Waters 3100 ESI-MS module, using a XTerraMS C18 5μm, 4.6×50 mm
column at a flow rate of 5 ml/min with a linear gradient (95% A: 5% B to 100% B 90sec and
30sec hold at 100% B, solvent A = water + 0.1% formic acid, solvent B = acetonitrile +
0.1% formic acid).
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Preparation of crebinostat (7-(2-([1,1′-biphenyl]-4-ylmethylene)hydrazinyl)-N-hydroxy-7-
oxoheptanamide)
4-phenyl benzaldehyde (1.16 g, 6.34 mmol) was added to a solution of amine hydroxamic
acid linker, 7-hydrazinyl-N-hydroxy-7-oxoheptanamide (1.0 g, 5.28 mmol) in methanol (25
ml) in a round bottom flask. A catalytic amount of difluoroacetic acid (20 μl) was added
into the reaction mixture and the solution was stirred for 1 hr at room temperature. The solid
precipitate was filtered out and purified by recrystallization from methanol to yield the
desired product, crebinostat, as a white solid (1.232 g, 66% yield). Purity was checked by
LC/MS and 1H NMR spectra from Varian 400 MHz FT NMR (Supplementary Figure 2). 1H
NMR (400 MHz, DMSO-d6) δ ppm relative to TMS 8.67 (s, 1H, CH-benzylidenimin), 8.18
(s, 1H, NH-sec. amide), 8.00 (s, 1H, NH-sec. amide), 7.68-7.74 (m, 6H), 7.45-7.49 (t, 2H, J
= 8 Hz), 7.36-7.39 (t, 1H, J = 6 Hz), 3.14-3.16 (bs, 2H), 2.48-2.49 (bs, 2H), 1.49-1.59 (m,
4H), 1.22-1.31 (bs, 2H).
Statistical analysis
Details on the specific statistical model used in each experiment can be found in the figure
legends.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
AcH4K12 acetylated histone H4 lysine 12
AcH3K9 acetylated histone lysine 9
Bdnf (brain-derived neurotrophic factor)
CRE cAMP response element
CREB cAMP response element-binding protein
CBP CREB binding protein
Egr1 early growth response 1
Grn (granulin)
HDAC histone deacetylase
Mapt (tau)
SAHA suberoylanilide hydroxamic acid
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Highlights
• Identified “crebinostat”, a novel HDAC inhibitor, in a CREB reporter gene
screen.
• Crebinostat inhibits HDACs 1-3 and 6; and induces histone acetylation.
• Crebinostat regulates neuronal genes involved in synaptic function and
cognition.
• Crebinostat enhances performance in fear conditioning learning in mice.
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Figure 1. Discovery of crebinostat in a CREB reporter gene assay screen
(A) Prototypical pathway for regulation of the CREB reporter gene by cAMP. cAMP
generated by adenylate cyclase induces protein kinase A (PKA) to phosphorylate and
activate CREB. Phosphodiesterase (PDE) activity degrades cAMP and terminates activation
of the pathway. This reporter gene has exquisite sensitivity to reveal the bioactivity of two
well-known small molecule modulators of adenylate cyclase and PDE, respectively:
forskolin and rolipram (Hagiwara et al., 1992; Xia et al., 2009). (B) Induction of CREB
reporter gene activity measured through a β-galactosidase luminescence assay in a stable
PC12 cell line by forskolin and trichostatin A (4 hr treatments) in cultures grown in 384-well
microtiter plates. *** = p < 0.0001, ** = p < 0.001 (one-way ANOVA; post hoc tests with
Bonferroni correction). (C) Synthetic strategy for generation of a library of novel
compounds structurally biased towards inhibition of HDACs. Cap and linker-biasing
element building blocks were mixed in DMSO and incubated at 60°C for 12 hours to
promote coupling to form the final novel compounds as products. The lower boxes show
examples of both types of building blocks used in the library. (D) Novel HDAC inhibitor
compounds were tested (20 μM; 4 hrs treatment; n=2), in the presence of forskolin (10 μM)
using CREB reporter PC12 cells. Levels of compound-induced activity were normalized to
DMSO in the absence or presence of forskolin. Inset shows location of crebinostat in the
primary CREB reporter gene screen with its strong activation of the reporter only in the
presence of forskolin.
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Figure 2. Crebinostat potently increases histone acetylation in neurons
(A) High-throughput neuronal histone acetylation immunofluorescence assay. Mouse
forebrain (image from the Allen Brain Atlas—www.brain-map.org) primary cultures were
grown in 96-well plates, treated with crebinostat or DMSO for 24 hrs, and then fixed and
stained for AcH4K12 or AcH3K9 according to standard immunofluorescence methods.
Histone acetylation signals were detected using laser scanning cytometer. (B) Dose response
plots for induction of histone acetylation in cultured primary mouse neurons by crebinostat
and SAHA for 24 hrs. EC50 values were 0.29 μM and 1.9 μM (AcH4K12) and 0.18 μM and
1.0 μM (AcH3K9) for crebinostat and SAHA, respectively. (C) Western blot analysis of
chromatin extracted from cultured primary mouse neurons treated with crebinostat (1 μM)
for 24 hrs using a general anti-acetylated lysine antibody that recognizes acetylated histone
H3, H4, H2A, and H2B. Crebinostat strongly increases the acetylation of all four major
components of nuclesomes in neurons.
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Figure 3. Crebinostat enhances memory of contextual fear conditioning in mice
(A) Concentration of crebinostat in the brain following IP injection. (B) Timeline of
contextual fear conditioning paradigm. Intraperitoneal injections of vehicle or crebinostat
(25 mg/kg) were given once daily for 10 days. On day 11, animals were trained in the
contextual fear conditioning paradigm and then given one more injection one hour after the
training. Animals were then tested for conditioned “freezing” behavior 24 hrs later on day
12 by re-exposure to the conditioning context. (C) Quantification of freezing behavior for
vehicle or crebinostat-treated mice. Data are mean percent freezing; n = 10 animals per
group. *** = p < 0.001 (unpaired t-test). (D) Quantification of exploratory open field
locomotion (horizontal movement) during the three minutes immediately prior to the
footshock. n.s. = not statistically significant (unpaired t-test). Data shown are from one
representative experiment; these results were reproduced in three separate experiments
analyzed independently by two trained experts.
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Figure 4. Crebinostat induces the immediate early gene Egr1
(A) Upper panel: Neuronal Egr1-EGFP reporter gene. Egr1 responds robustly and rapidly to
a variety of neuronal signaling events via the action of kinase cascades on three signal-
responsive transcription factors that bind to its proximal promoter: CREB, SRF/ELK1
ternary complex (serum response factor/Ets-like transcription factor 1); and SP1 (specificity
protein 1). Lower panel: Activation of the Egr1-EGFP reporter gene by crebinostat and
SAHA in primary cultured cortical neurons. Cortical neurons were treated for 24 hours at
the indicated doses. The graph illustrates the dose response for induction of EGFP
fluorescence by crebinostat and SAHA (mean +/- standard deviation). (B) Representative
images of neuronal EGFP fluorescence (20X magnification) from DMSO and crebinostat
treated cultures. (C) Induction of endogenous Egr1 mRNA in mouse forebrain primary
cultures by 24 hrs treatment with crebinostat. Egr1 mRNA levels measured by RT-PCR
were normalized to Gapdh mRNA levels and then plotted as fold change versus the DMSO
condition. * = p < 0.05 (unpaired t-test).
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Figure 5. Regulation of the neuronal transcriptome by crebinostat treatment
(A) Volcano plot of normalized Illumina microarray data from RNA samples made from
mouse forebrain primary cultured neurons treated for 24 hrs with DMSO vehicle or
crebinostat (1 μM). Upregulated or downregulated transcripts meeting a statistical
significance threshold (p < 0.05) are indicated in red. (B) Pie chart reflecting the total
number of transcripts up- or down-regulated by crebinostat. (C and D) Protein-protein
interaction network reveals connectivity of synaptic CREB target genes up- or down-
regulated by crebinostat. Nodes (circles) represent proteins encoded by the crebinostat
regulated genes and edges (lines) connecting nodes represent known protein-protein
interactions. Modules consisting of nodes with related functions are circled.
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Figure 6. Crebinostat increases histone acetylation and synapsin I punctae along dendrites in
primary cultured neurons
Immunofluorescence staining of neurons treated for 24 hrs with DMSO as a vehicle (A, C,
E) or crebinostat (1 μM) (B, D, G) for a dendrite marker (Map2, in red); acetyl-histone H4
lysine 12 (magenta); and synapsin I (green). Scale bar = 50 μm. (C, D) Enlarged view from
representative images of dendrites with synapsin I punctae. (E, G) Enlarged nuclei stained
for acetyl-histone H4 lysine 12 (AcH4K12). Scale bar = 10 μm. (F, H) Histogram showing
the frequency distribution of average acetyl-histone H4 lysine 12 (AcH4K12) fluorescence
intensity levels in nuclei. N = 10 (DMSO) or 28 (1 μM crebinostat). Green bar = mean
intensity; red bar = threshold chosen to define “high” acetylation levels. (I) Quantification of
mean nuclear acetyl-histone H4, lysine12 fluorescence intensity levels after 24 hrs DMSO or
crebinostat treatment. (J) Quantification of percentage of nuclear area with high levels of
acetyl-histone H4, lysine12 signal. A nuclear pixel was defined as having a “high” level of
acetylation if it had a signal intensity ≥ a threshold of 27 (arbitrary units; indicated by red
line in panels F and H). *** = p < 0.001 (unpaired t-test).
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Figure 7. Crebinostat increases synapsin I punctae density along dendrites
(A) Representative immunofluorescence images of neurons stained for the dendrite marker
Map2 and synapsin I following 24 hr treatments with DMSO or crebinostat (1 μM). The
right panel shows the overlay of the two images (Map2 in red; synapsin I in green). Scale
bar = 50 μm. ImageJ analysis was used to quantify the density of synapsin I punctae along
Map2-positive dendrites (B), the total amount of Map2-positive dendritic length per field (*
= p < 0.05; unpaired t-test) (C), the frequency distribution of the size of synapsin I punctae
(D), and the frequency distribution of the mean signal intensity for synapsin I staining in
punctae (E). 15 fields from three independent cultures were analyzed for each graph.
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Figure 8. Regulation of granulin, tau, Hsp70, and BDNF gene expression by crebinostat
Primary cultured mouse forebrain neurons were treated for 24 hours with DMSO or
crebinostat (1 μM). A) Grn (granulin), B) Mapt (tau), C) Hspa1b (Hsp70), and D) Bdnf
transcript IV mRNA levels were measured using TaqMan real time PCR assays and
normalized to Gapdh mRNA levels. *** = p < 0.001 (unpaired t-test).
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Figure 9. Potential models of regulation of CREB-dependent transcription, synaptic function,
and memory by HDACs
“Ac” marks acetylation events reported in the literature that are likely to be key control
points for CREB activity. HDACs may regulate CREB-dependent transcription by reversing
any of these acetylation events. CBP = CREB-binding protein; PP1 = protein phosphatase 1;
H2A, H2B, H3, and H4 = histone protein N-terminal tails.
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Table 2
CREB-target genes upregulated by crebinostat.
Gene
Fold
upregulation
(Illumina array)
Fold
upregulation
(RT-PCR)
CREB target
gene reference
Function
(reference)
Egr1 - 3.9 Kim et al., 2010
inducible
transcription
factor
(Malkani et al., 2004
Sdcbp 2.2 2.3 Martianov et al., 2010
synapse
formation
in development
(Hirbec et al., 2005)
Sema5a 2.1 3.6 Martianov et al., 2010 axon guidance(Kantor et al., 2004)
Aldh2 2.0 2.3 MacGillavry et al., 2011
neuronal
mitochondrial
detoxification
(Ohsawa et al., 2008)
Pik3c3 1.6 2.2 Martianov et al., 2010
dendritic spine
stability
(Wang et al., 2011)
Fzd5 1.6 5.2 Martianov et al., 2010
Wnt-mediated
synaptogenesis
(Sahores et al., 2010)
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